FacebookTwitterGoogle+RedditEmail

Can Wyeth Fool American Women Twice?

Can Wyeth win back the 40 million Premarin and Prempro users it’s lost since 2002–along with $1 billion a year in profits–with a new menopause drug?

Or will the once-bitten women who have filed more than 5,000 law suits claiming the hormones gave them cancer feel fooled twice?

Pristiq, a serotonin/norepinephrine reuptake inhibitor (SNRI), is a metabolite of Wyeth’s antidepressant Effexor XR–which netted $3.7 billion in 2006–and an unabashed patent extender since Effexor XR goes off patent in 2010.

In February Pristiq was approved by the FDA for the treatment of adults with major depressive disorder but its launch as the first non-hormonal treatment for menopausal symptoms is what Wyeth hopes will fill the Premarin/Prempro/Effexor black hole to the tune of $2 billion a year.

Unfortunately, instead of a green light to market Pristiq for menopause last July, the FDA–also once bitten after Vioxx, Avandia and Vytroin–said to Wyeth not so fast.

Why did two women in the study group taking Pristiq have heart attacks and three need procedures to repair clogged arteries compared with none taking placebo it wanted to know? How can Wyeth assure long term safety when 604 of the 2,158 test subjects took Pristiq for only six months and 318 for a year or more? And what about serious liver complications seen in the studies?

Nor do drug industry insiders on the chatroom cafepharma sound like they’re scooping up Wyeth stock.

“Pristiq is not a good drug by any standard,” wrote one anonymous poster. “We tried to get 100 mg approved as the standard dose. But our patients got so sick that they could care less about the efficacy. They just couldn’t tolerate the drug long enough to see any improvement.”

Like longer than six months?

“No study exists showing any anti-depressant including Pristiq works any better than a placebo for reducing hot flashes, which are subjective anyway and only last a few minutes long at worst,” wrote another anonymous poster. “That is a heavy price to pay to take a heavy duty drug 24/7 for a few minutes of daily relief that a sugar pill also provides. FDA is crazy (or bought) if they allow this unproven drug travesty on the market.”

A third poster predicted women wouldn’t trade, “hot flashes for decreased libido, nausea, increased blood pressure and incredible withdrawal issues,” found with Pristiq. “Women and their physicians are not as gullible as they were back in the Premarin days.”

Even psychiatrist Daniel Carlat who wrote an expose for the New York Times magazine called Dr. Drug Rep last year about his experiences as a Wyeth paid spokesman, is dissing Pristiq.

“Every patient who takes Effexor produces Pristiq in their own body, at no additional charge,” he writes in a blog article called Top 5 Reasons to Forget About Pristiq.

Moreover Wyeth’s own investigator on the major Pristiq trials, Dr. Michael Liebowitz, admits it is “not a revolutionary drug” writes Carlat.

Of course you can’t blame a one trick company that cut its teeth on the Feminine Forever idea that age in women is a disease that needs treating for churning the demographics. Especially as it lays off 1,200 US workers, closes manufacturing plants and fights for its life.

Was it Wyeth’s fault that the hormone “therapy” it pushed for decades actually increases breast cancer by 26 percent, heart attacks by 29 percent, stroke by 41 percent and doubles the risk of blood clots and dementia?

But if US women embrace a major psychiatric drug with possible liver and heart complication side effects after the hormone hoax–manufactured by the same company and at four times the cost of Prempro/Premarin, $4 per day–

Fool me twice–?

MARTHA ROSENBERG is staff cartoonist on the Evanston Roundtable. She can be reached at mrosenberg@evmark.org

 

Your Ad Here
 

 

 

 

 

More articles by:

Martha Rosenberg is an investigative health reporter. She is the author of  Born With A Junk Food Deficiency: How Flaks, Quacks and Hacks Pimp The Public Health (Prometheus).

April 19, 2018
Ramzy Baroud
Media Cover-up: Shielding Israel is a Matter of Policy
Vijay Prashad
Undermining Brazilian Democracy: the Curious Saga of Lula
Steve Fraser
Class Dismissed: Class Conflict in Red State America
John W. Whitehead
Crimes of a Monster: Your Tax Dollars at Work
Kenn Orphan
Whistling Past the Graveyard
Karl Grossman - TJ Coles
Opening Pandora’s Box: Karl Grossman on Trump and the Weaponization of Space
Colin Todhunter
Behind Theresa May’s ‘Humanitarian Hysterics’: The Ideology of Empire and Conquest
Jesse Jackson
Syrian Strikes is One More step Toward a Lawless Presidency
Michael Welton
Confronting Militarism is Early Twentieth Century Canada: the Woman’s International League for Peace and Freedom
Alycee Lane
On David S. Buckel and Setting Ourselves on Fire
Jennifer Matsui
Our Overlords Reveal Their Top ‘To Do’s: Are YOU Next On Their Kill List?
George Ochenski
Jive Talkin’: On the Campaign Trail With Montana Republicans
Kary Love
Is It Time for A Nice, “Little” Nuclear War?
April 18, 2018
Alan Nasser
Could Student Loans Lead to Debt Prison? The Handwriting on the Wall
Susan Roberts
Uses for the Poor
Alvaro Huerta
I Am Not Your “Wetback”
Jonah Raskin
Napa County, California: the Clash of Oligarchy & Democracy
Robert Hunziker
America’s Dystopian Future
Geoffrey McDonald
“America First!” as Economic War
Jonathan Cook
Robert Fisk’s Douma Report Rips Away Excuses for Air Strike on Syria
Jeff Berg
WW III This Ain’t
Binoy Kampmark
Macron’s Syria Game
Linn Washington Jr.
Philadelphia’s Top Cop Defends Indefensible Prejudice in Starbucks Arrest Incident
Katie Fite
Chaos in Urban Canyons – Air Force Efforts to Carve a Civilian Population War Game Range across Southern Idaho
Robby Sherwin
Facebook: This Is Where I Leave You
April 17, 2018
Paul Street
Eight Takeaways on Boss Tweet’s Latest Syrian Missile Spasm
Robert Fisk
The Search for the Truth in Douma
Eric Mann
The Historic 1968 Struggle Against Columbia University
Roy Eidelson
The 1%’s Mind Games: Psychology Gone Bad
John Steppling
The Sleep of Civilization
Patrick Cockburn
Syria Bombing Reveals Weakness of Theresa May
Dave Lindorff
No Indication in the US That the Country is at War Again
W. T. Whitney
Colombia and Cuba:  a Tale of Two Countries
Dean Baker
Why Isn’t the Median Wage for Black Workers Rising?
Linn Washington Jr.
Philadelphia’s Top Cop Defends Indefensible Prejudice in Starbucks Arrest Incident
C. L. Cook
Man in the Glass
Kary Love
“The Mob Boss Orders a Hit and a Pardon”
Lawrence Wittner
Which Nations Are the Happiest―and Why
Dr. Hakim
Where on Earth is the Just Economy that Works for All, Including Afghan Children?
April 16, 2018
Dave Lindorff
President Trump’s War Crime is Worse than the One He Accuses Assad of
Ron Jacobs
War is Just F**kin’ Wrong
John Laforge
Nuclear Keeps on Polluting, Long After Shutdown
Norman Solomon
Missile Attack on Syria Is a Salute to “Russiagate” Enthusiasts, Whether They Like It or Not
Uri Avnery
Eyeless in Gaza   
Barbara Nimri Aziz
Iraq Then, Syria Now
FacebookTwitterGoogle+RedditEmail